Literature DB >> 495730

Prostaglandin E2-induced hypertension in conscious dogs.

G M Hockel, A W Cowley.   

Abstract

The effects of continuous intrarenal prostaglandin E2 (PGE2) infusion (7 days) on sodium and water balance, plasma renin activity (PRA), and sodium and water balance, plasma renin activity (PRA), and mean arterial pressure (MAP) were examined in conscious, unilaterally nephrectomized dogs maintained on a fixed sodium intake of 55 meq/day. PGE2 infusion (2 microgram/min) resulted in a sustained threefold increase in both urine output and water intake without a measurable change in glomerular filtration rate. PRA increased from 0.4 +/- 0.1 during the control period to 2.2 +/- 0.9 ng AI.ml-1.h-1 on day 1 and averaged 3.6 +/- 0.5 for the remaining 6 days of PGE2 infusion. Concurrently, MAP increased from 102 +/- 3 to a maximum of 117 +/- 4 mmHg on day 5; changes in PRA and MAP were significantly correlated (r = 0.96, P less than 0.001). Sodium excretion increased from 54.5 +/- 3 to 88.0 +/- 19 meq/day on day 1, and then declined to an average of 64.8 +/- 1 meq/day for the remaining 6 days of infusion. All variables returned to the control level during the recovery period. Intravenous infusion of PGE2 (2 microgram/min) yielded directionally similar but statistically insignificant effects. It is concluded that chronic intrarenal PGE2 infusion results in marked diuresis, polydipsia, a moderate loss of sodium, enhanced PRA, and mild hypertension.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 495730     DOI: 10.1152/ajpheart.1979.237.4.H449

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  Prostaglandin E2 modulation of blood pressure homeostasis: studies in rodent models.

Authors:  Christina E Swan; Richard M Breyer
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-07-27       Impact factor: 3.072

2.  Angiotensin type 1 receptor mediates renal production and conversion of prostaglandins E2 to F2α in conscious diabetic rats.

Authors:  Peter M Abadir; Helmy M Siragy
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2015-07-20       Impact factor: 1.636

3.  Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility.

Authors:  Lihong Chen; Yifei Miao; Yahua Zhang; Dou Dou; Limei Liu; Xiaoyu Tian; Guangrui Yang; Dan Pu; Xiaoyan Zhang; Jihong Kang; Yuansheng Gao; Shiqiang Wang; Matthew D Breyer; Nanping Wang; Yi Zhu; Yu Huang; Richard M Breyer; Youfei Guan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311

4.  EP1 disruption attenuates end-organ damage in a mouse model of hypertension.

Authors:  Christina S Bartlett; Kelli L Boyd; Raymond C Harris; Roy Zent; Richard M Breyer
Journal:  Hypertension       Date:  2012-09-24       Impact factor: 10.190

5.  Regulation of arterial reactivity by concurrent signaling through the E-prostanoid receptor 3 and angiotensin receptor 1.

Authors:  Maria P Kraemer; Hyehun Choi; Jeff Reese; Fred S Lamb; Richard M Breyer
Journal:  Vascul Pharmacol       Date:  2016-05-31       Impact factor: 5.773

6.  A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus.

Authors:  Jian Hua Li; Chung-Lin Chou; Bo Li; Oksana Gavrilova; Christoph Eisner; Jürgen Schnermann; Stasia A Anderson; Chu-Xia Deng; Mark A Knepper; Jürgen Wess
Journal:  J Clin Invest       Date:  2009-10       Impact factor: 14.808

7.  Acute effects of prostaglandin E1 and E2 on vascular reactivity and blood flow in situ in the chick chorioallantoic membrane.

Authors:  D R Harland; L D Lorenz; K Fay; B E Dunn; S K Gruenloh; J Narayanan; E R Jacobs; M Medhora
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2012-08-02       Impact factor: 4.006

Review 8.  Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.

Authors:  Serena Milano; Monica Carmosino; Andrea Gerbino; Maria Svelto; Giuseppe Procino
Journal:  Int J Mol Sci       Date:  2017-11-10       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.